Date: 2018-05-15
Type of information: Nomination
Compound: chief scientific officer
Company: Five Prime Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 15, 2018, Five Prime Therapeutics announced the appointment of Bryan Irving, Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Irving joined Five Prime in August 2017 as the Vice President of Research. Prior to joining Five Prime, Dr. Irving was at CytomX Therapeutics,
where he most recently served as Vice President of Cancer Immunology, leading efforts to generate protease-activatable immunotherapies designed to mobilize anti-tumor immunity locally in the tumor microenvironment. His research has focused primarily on exploring ways to modulate T cell activity for therapeutic benefit in both autoimmune and oncology settings. Dr. Irving's doctoral work, performed in the laboratory of Dr. Art Weiss at University of California, San Francisco (UCSF), pioneered the single-chain chimeric antigen receptor (CAR) technology now being used in patients’ T cells to treat hematologic malignancies. Following post-doctoral work at Harvard and UCSF on early T cell development, Dr. Irving joined Genentech in 2001 where he worked for 12 years in a joint appointment with the Departments of Immunology and Oncology/Cancer Immunotherapy. Dr. Irving left Genentech in 2013 to join CytomX Therapeutics.
- Dr. Irving received a Ph.D. in Immunology from the University of California, San Francisco and a B.A. in Physiology from the University of California,
Berkeley. In addition, Dr. Irving studied clarinet at the Eastman School of Music at the University of Rochester.
Financial terms:
Latest news:
Is general: Yes
